Intellia Reports Lasting Gene-Editing Effects in Four-Year Follow-Up
Text
An update on experimental hereditary angioedema treatment.
Intellia says all 32 Phase 1/2 participants were off long-term preventive medication at cutoff after one lonvo-z treatment.
The experimental hereditary angioedema therapy disables KLKB1, a gene involved in producing plasma kallikrein.
That protein fell 84% on average at four weeks, with reductions sustained through follow-up reaching four years. Individual follow-up lengths varied.
The company-reported results suggest a path away from continuous preventive medication. The treatment remains in development.
Original source published: Intellia, November 12, 2026
Share this article
What do you think of this story?
Anonymous feedback, up to 5 reactions per article.
Anonymous comments
Share your thoughts without signing in.
Discuss the technology and the story. Hate, politics and war, threats, abuse, personal accusations, sexual content, ads, links and personal information are not allowed.
No comments yet. Be the first to share.